Literature DB >> 15960598

Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons.

Shaoheng Ni1, Kathrin Bernt, Anuj Gaggar, Zong-Yi Li, Hans-Peter Kiem, André Lieber.   

Abstract

Vectors containing group B adenovirus (Ad) fibers are able to efficiently transduce gene therapy targets that are refractory to infection with standard Ad serotype 5 (Ad5) vectors, including malignant tumor cells, hematopoietic stem cells, and dendritic cells. Preliminary studies in mice indicate that, after intravenous injection, B-group fiber-containing Ads do not efficiently transduce most organs and cause less acute toxicity than Ad5 vectors. However, biodistribution and safety studies in mice are of limited value because the mouse analog of the B-group Ad receptor, CD46, is expressed only in the testis, whereas in humans, CD46 is expressed on all nucleated cells. Unlike mice, baboons have CD46 expression patterns and levels that closely mimic those in humans. We conducted a biodistribution and toxicity study of group B Ad fiber-containing vectors in baboons. Animals received phosphate-buffered saline, Ad5-bGal (a first-generation Ad5 vector), or B-group fiber-containing Ads (Ad5/35-bGal and Ad5/11-bGal) at a dose of 2 x 10(12) VP/kg, and vector biodistribution and safety was analyzed over 3 days. The amount of Ad5/35-bGal and Ad5/11-bGal vector genomes was in most tissues one to three orders of magnitude below that of Ad5. Significant Ad5/35- and Ad5/11-mediated transgene (beta-galactosidase) expression was seen only in the marginal zone of splenic follicles. Compared with the animal that received Ad5-bGal, all animals injected with B-group fiber-containing Ad vectors had lower elevations in serum proinflammatory cytokine levels. Gross and histopathology were normal in animals that received B-group Ad fiber-containing Ads, in contrast to the Ad5-infused animal, which showed widespread endothelial damage and inflammation. In a further study, a chimeric Ad5/35 vector carrying proapoptotic TRAIL and Ad E1A genes under tumor-specific regulation was well tolerated in a 30-day toxicity study. No major clinical, serologic, or pathologic abnormalities were noticed in this animal.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15960598      PMCID: PMC1351080          DOI: 10.1089/hum.2005.16.664

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  56 in total

1.  Artificial mutations and natural variations in the CD46 molecules from human and monkey cells define regions important for measles virus binding.

Authors:  E C Hsu; R E Dörig; F Sarangi; A Marcil; C Iorio; C D Richardson
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo.

Authors:  D A Muruve; M J Barnes; I E Stillman; T A Libermann
Journal:  Hum Gene Ther       Date:  1999-04-10       Impact factor: 5.695

3.  The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors.

Authors:  A Lieber; C Y He; L Meuse; D Schowalter; I Kirillova; B Winther; M A Kay
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Experimental measles. I. Pathogenesis in the normal and the immunized host.

Authors:  M B McChesney; C J Miller; P A Rota; Y D Zhu; L Antipa; N W Lerche; R Ahmed; W J Bellini
Journal:  Virology       Date:  1997-06-23       Impact factor: 3.616

5.  Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: involvement of NFkappaB.

Authors:  P Löser; G S Jennings; M Strauss; V Sandig
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

6.  Levels of complement regulatory proteins, CD35 (CR1), CD46 (MCP) and CD55 (DAF) in human haematological malignancies.

Authors:  T Hara; A Kojima; H Fukuda; T Masaoka; Y Fukumori; M Matsumoto; T Seya
Journal:  Br J Haematol       Date:  1992-10       Impact factor: 6.998

7.  The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues.

Authors:  L Thorsteinsson; G M O'Dowd; P M Harrington; P M Johnson
Journal:  APMIS       Date:  1998-09       Impact factor: 3.205

8.  Identification and characterization of membrane cofactor protein of human spermatozoa.

Authors:  F Cervoni; T J Oglesby; E M Adams; C Milesifluet; M Nickells; P Fenichel; J P Atkinson; B L Hsi
Journal:  J Immunol       Date:  1992-03-01       Impact factor: 5.422

9.  Inhibition of NF-kappaB activation in combination with bcl-2 expression allows for persistence of first-generation adenovirus vectors in the mouse liver.

Authors:  A Lieber; C Y He; L Meuse; C Himeda; C Wilson; M A Kay
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

10.  Expression of membrane cofactor protein (MCP, CD46) in human liver diseases.

Authors:  N Kinugasa; T Higashi; K Nouso; H Nakatsukasa; Y Kobayashi; M Ishizaki; N Toshikuni; K Yoshida; S Uematsu; T Tsuji
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

View more
  44 in total

1.  Fiber and penton base capsid modifications yield diminished adenovirus type 5 transduction and proinflammatory gene expression with retention of antigen-specific humoral immunity.

Authors:  John W Schoggins; Erik Falck-Pedersen
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

Review 2.  Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications.

Authors:  Zachary C Hartman; Daniel M Appledorn; Andrea Amalfitano
Journal:  Virus Res       Date:  2007-11-26       Impact factor: 3.303

3.  Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses.

Authors:  Karin Loré; William C Adams; Menzo J E Havenga; Melissa L Precopio; Lennart Holterman; Jaap Goudsmit; Richard A Koup
Journal:  J Immunol       Date:  2007-08-01       Impact factor: 5.422

4.  Fiber shaft-chimeric adenovirus vectors lacking the KKTK motif efficiently infect liver cells in vivo.

Authors:  Nelson C Di Paolo; Oleksandr Kalyuzhniy; Dmitry M Shayakhmetov
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

5.  Adenovirus encoding human platelet-derived growth factor-B delivered to alveolar bone defects exhibits safety and biodistribution profiles favorable for clinical use.

Authors:  Po-Chun Chang; Joni A Cirelli; Qiming Jin; Yang-Jo Seol; James V Sugai; Nisha J D'Silva; Theodora E Danciu; Lois A Chandler; Barbara A Sosnowski; William V Giannobile
Journal:  Hum Gene Ther       Date:  2009-05       Impact factor: 5.695

6.  In vivo HSPC gene therapy with base editors allows for efficient reactivation of fetal γ-globin in β-YAC mice.

Authors:  Chang Li; Aphrodite Georgakopoulou; Arpit Mishra; Sucheol Gil; R David Hawkins; Evangelia Yannaki; André Lieber
Journal:  Blood Adv       Date:  2021-02-23

7.  A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy.

Authors:  Hongjie Wang; Ying Liu; Zong-Yi Li; Xiaolong Fan; Akseli Hemminki; André Lieber
Journal:  Blood       Date:  2009-11-12       Impact factor: 22.113

8.  Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system.

Authors:  Zachary C Hartman; Daniel M Appledorn; Delila Serra; Oliver Glass; Todd B Mendelson; Timothy M Clay; Andrea Amalfitano
Journal:  Virology       Date:  2008-02-15       Impact factor: 3.616

9.  Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model.

Authors:  Anurag Sharma; Dinesh S Bangari; Manish Tandon; Aseem Pandey; Harm HogenEsch; Suresh K Mittal
Journal:  Virology       Date:  2009-02-10       Impact factor: 3.616

10.  Evaluation of biodistribution and safety of adenovirus vector containing MDR1 in mice.

Authors:  ZhenZhen Zhao; Wei Liu; Yuxi Su; Jin Zhu; GaiHuan Zheng; Qing Luo; XianQing Jin
Journal:  J Exp Clin Cancer Res       Date:  2010-01-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.